Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lantern Pharma Inc (LTRN)

Lantern Pharma Inc (LTRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,439
  • Shares Outstanding, K 10,741
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,960 K
  • 60-Month Beta 1.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.53
Trade LTRN with:

Options Overview Details

View History
  • Implied Volatility 140.92% ( -65.75%)
  • Historical Volatility 170.61%
  • IV Percentile 83%
  • IV Rank 67.29%
  • IV High 206.67% on 04/22/24
  • IV Low 5.68% on 07/07/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 142
  • Volume Avg (30-Day) 237
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 2,370
  • Open Int (30-Day) 3,841

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.43
  • Number of Estimates 1
  • High Estimate -0.43
  • Low Estimate -0.43
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -19.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.20 +16.44%
on 04/19/24
11.99 -49.50%
on 03/25/24
-4.59 (-43.15%)
since 03/22/24
3-Month
3.85 +57.27%
on 02/23/24
11.99 -49.50%
on 03/25/24
+1.92 (+46.61%)
since 01/23/24
52-Week
2.38 +154.41%
on 11/01/23
11.99 -49.50%
on 03/25/24
+1.17 (+24.08%)
since 04/21/23

Most Recent Stories

More News
Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth

EQNX::TICKER_START (OTCQB:TREIF),(CSE:TRUE),(NYSE:MDT),(NASDAQ:NVDA),(NASDAQ:LTRN),(OTCQX:HWAIF),(TSX:AIDX) EQNX::TICKER_END

TREIF : 0.5246 (-1.02%)
TRUE.CN : 0.7100 (-1.39%)
NVDA : 817.17 (+2.77%)
HWAIF : 1.1400 (-1.30%)
AIDX.TO : 1.57 (unch)
LTRN : 6.07 (+6.12%)
MDT : 80.79 (+0.27%)
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

EQNX::TICKER_START (OTCQB:TREIF),(CSE:TRUE),(OTCQX:HWAIF),(OTCQB:VRSSF),(NYSE:PATH),(NASDAQ:LTRN) EQNX::TICKER_END

VERS.NE : 0.9900 (unch)
TREIF : 0.5246 (-1.02%)
TRUE.CN : 0.7100 (-1.39%)
HWAIF : 1.1400 (-1.30%)
AIDX.TO : 1.57 (unch)
VRSSF : 0.7126 (-0.81%)
VERS : 38.41 (+1.99%)
PATH : 19.46 (+3.02%)
LTRN : 6.07 (+6.12%)
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

TREIF : 0.5246 (-1.02%)
TRUE.CN : 0.7100 (-1.39%)
HWAIF : 1.1400 (-1.30%)
AIDX.TO : 1.57 (unch)
VRSSF : 0.7126 (-0.81%)
VERS : 38.41 (+1.99%)
PATH : 19.46 (+3.02%)
LTRN : 6.07 (+6.12%)
8 Best Artificial Intelligence Stocks Under $10

If you want to get in on artificial intelligence (AI) but don’t want to spend a lot, why not consider artificial intelligence stocks under $10? Learn more.

C : 62.46 (+2.48%)
GME : 10.19 (+1.80%)
INTC : 34.38 (-0.09%)
LRCX : 885.17 (+1.97%)
LTRN : 6.07 (+6.12%)
MSFT : 406.35 (+1.34%)
MOVE : 0.4839 (+3.18%)
NVDA : 817.17 (+2.77%)
TSLA : 145.64 (+2.53%)
AMD : 152.18 (+2.38%)
NIO : 4.06 (+1.50%)
NOTE : 1.2200 (+4.27%)
Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace,...

LTRN : 6.07 (+6.12%)
Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost,...

LTRN : 6.07 (+6.12%)
Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost,...

LTRN : 6.07 (+6.12%)
Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost,...

LTRN : 6.07 (+6.12%)
Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost,...

LTRN : 6.07 (+6.12%)
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost,...

LTRN : 6.07 (+6.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas.

See More

Key Turning Points

3rd Resistance Point 6.81
2nd Resistance Point 6.40
1st Resistance Point 6.06
Last Price 6.07
1st Support Level 5.31
2nd Support Level 4.91
3rd Support Level 4.57

See More

52-Week High 11.99
Fibonacci 61.8% 8.32
Fibonacci 50% 7.18
Last Price 6.07
Fibonacci 38.2% 6.05
52-Week Low 2.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar